Case Studies of Analgesic Cannabinoid Use by Persons with Chronic Pain from Car Accidents

Zack Zdenek Cernovsky; Larry Craig Litman

doi:7400202

Reviews recent research on cannabinoids, especially on cannabidiol (CBD) with respect to its neuroprotective properties and its long term effect on injured tissues and associated chronic pain, and presents case studies of two men (age 52 and 53) involved in multiple car accidents. They suffered from severe chronic pain, pain related insomnia, the post-concussion syndrome, and various neurological symptoms such as urinary incontinence. One of them inhaled vaporized cannabis oil of unknown composition, experienced major pain relief over time, and as a side-effect, unexpectedly and fully recovered from his terminal pulmonary cancer. The other man suffered from a cardiac arrest after which the cardiologist discontinued his prescription of hydromorphone of several years: this patient then started to use CBD oil in 1:1 ratio with tetrahydrocannabinol (THC), and experienced not only substantial pain relief, but also appeared more cognitively alert. Both patients reported that these cannabinoids provided more adequate relief from pain than their previously prescribed analgesics.

[1]

Cernovsky Z, Istasy P, Bureau Y, & Chiu S. Scale for retrospective assessment of immediate concussion symptoms. Mental Illness, 2018; 10 (2): 70-71 and Appendix (2 pages). https://doi.org/10.4081/mi.2018.7901 and https://www.pagepress.org/journals/index.php/mi/article/view/7901/7661.

[2]

Lu HC and Mackie K. An introduction to the endogenous cannabinoid system. Biological Psychiatry. 2016; 1; 79 (7): 516–525. doi: 10.1016/j.biopsych. 2015.07.028.

[3]

Pagotto U, Marsicano G, Cota D, Lutz BG, Pasquali R. The Emerging Role of the Endocannabinoid System in Endocrine Regulation and Energy Balance. Endocrine Reviews. 2006; 27 (1); 73-100. doi.org/10.1210/er.2005-0009.

[4]

Viudez Martínez A, García Gutiérrez MS, Medrano Relinque J, Navarrón CM, Navarrete F, and Manzanares J. Cannabidiol does not display drug abuse potential in mice behavior. Acta Pharmacologica Sinica. 2018; 0: 1-7. doi.org/10.1038/s41401 018 0032 8.

[5]

Viudez Martínez A, García Gutiérrez MS, Navarrón CM, Morales Calero MI, Navarrete F, Torres Suárez AI & Manzanares J. Cannabidiol reduces ethanol consumption, motivation and relapse in mice. Addiction Biology, 2017; 23: 154B164.

[6]

Viudez Martínez A, García Gutiérrez MS, Fraguas Sánchez AI, Torres Suárez AI, and Manzanares J. Effects of cannabidiol plus naltrexone on motivation and ethanol consumption. British Journal of Pharmacology. 2018; 175: 3369-3378.

[7]

Manzanares J, Gasparyan A, Caparros E, Navarrete F. Evaluation of cannabidiol effects in a new animal model of Post-Traumatic Stress Disorder. World Psychiatric Congress, Mexico City, Mexico, September 27-30, 2018.

[8]

Cernovsky Z, Elias RG. Case Reports of Successful Management of Pain by One to One Ratio of Cannabidiol with Tetrahydrocannabinol. Archives of Psychiatry and Behavioral Sciences. 2018; 1 (2): 4-36.

[9]

Elias RG, Raheb M, Mekhaiel D, Cernovsky Z, Sidhu G, Warren D, Sadek G, Chiu S, Bureau Y. Use of Pharmaceutical Analgesics Versus Cannabis or Cannabidiol-Tetrahydrocannabinol Oils to Reduce Pain. Archives of Psychiatry and Behavioral Sciences. 2018; 1 (2): 37-40.

[10]

Perucca E. Cannabinoids in the Treatment of Epilepsy: Hard Evidence at Last? Journal of Epilepsy Research. 2017; 7 (2): 61–76. doi: 10.14581/jer.17012.

[11]

Aran A, Cassuto H, Lubotzky A. Cannabidiol Based Medical Cannabis in Children with Autism - a Retrospective Feasibility Study (P 3.318). Neurology. April 10, 2018; 90 (15 Supplement).

[12]

Leweke FM, Piomelli D, Pahlisch F, Muhl D, Gerth CW, Hoyer C, Klosterkötter J, Hellmich M, Koethe D. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Translational Psychiatry, 2012; 2: e94. doi: 10.1038/tp.2012.15.

[13]

Alvarez FJ, Lafuente H, Rey-Santano MC, Mielgo VE, Gastiasoro E, Rueda M, Pertwee RG, Castillo AI, Romero J, Martínez-Orgado J. Neuroprotective effects of the nonpsychoactive cannabinoid cannabidiol in hypoxic-ischemic newborn piglets. Pediatric Research. 2008; 64 (6): 653-658. doi: 10.1203/PDR.0b013e318186e5dd.

[14]

Campos AC, Fogaça MV, Sonego AB, Guimarães FS. Cannabidiol, neuroprotection and neuropsychiatric disorders. Pharmacological Research. 2016; 112: 119-127. doi: 10.1016/j.phrs. 2016.01.033.

[15]

McAllister SD, Soroceanu L, and Desprez P-Y, The Antitumor Activity of Plant-Derived Non-Psychoactive Cannabinoids. Journal of Neuroimmune Pharmacology. 2015; 10: 255-267. doi 10.1007/s11481-015-9608-y.

[16]

Rubin R. The Path to the First FDA Approved Cannabis Derived Treatment and What Comes Next. Journal of the American Medical Association (JAMA). 2018; September 5: E1-E3.

[17]

Kuehn B. Synthetic cannabidiol poisoning. Journal of the American Medical Association (JAMA). 2018; 319 (22), 2264.

[18]

Jikomes N, and Zoorob M.. The Cannabinoid Content of Legal Cannabis in Washington State Varies Systematically Across Testing Facilities and Popular Consumer Products. Scientific Reports. 2018; 8: (4519), 1-15. doi: 10.1038/s41598-018-22755-2.

[19]

Prud’homme M, Cata R, Jutras-Aswad D. Cannabidiol as an Intervention for Addictive Behaviors: A Systematic Review of the Evidence. Substance Abuse: Research and Treatment. 2015; 9: 33-38. doi: 10.4137/SART. S25081.

[20]

Hill TD, Cascio MG, Romano B, et al. Cannabidivarin-rich cannabis extracts are anticonvulsant in mouse and rat via a CB1 receptor-independent mechanism. British Journal of Pharmacology. 2013; 170: 679-692.